Biswajit Das

Biswajit Das

Auto-generated profile, based on publicly available information

Biswajit Das

University of California, Santa Cruz

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Diseases & Research
Verified
Journal Article
Open access
PDF file
SLSwain Laxita
Swain Laxita
DBDas Biswajit
Das Biswajit
Natalia BaranNatalia Baran
Natalia Baran
Breast cancer is a leading cause of death among women worldwide due to its aggressive nature, early metastasis, and resistance to standard chemotherapy. Doxorubicin (DOX) is a potent anticancer drug and remains one of the most effective treatments for breast cancer. This review delves into the diverse anticancer attributes of DOX, encompassing its ability to induce DNA damage, provoke the production of reactive oxygen species, facilitate various mechanisms of cell death, and promote or enhance an anti-tumor immune response. Through an analysis of both monotherapy and combination therapy approaches, this review underscores the immense significance of DOX in contemporary breast cancer treatment. It also delves into the limitations of DOX-based therapies and provides insights into future perspectives for research and development in this field.

5 December 2025 in Cancer Heterogeneity and Plasticity
Verified
Journal Article
Open access
BDBiswajit Das
Biswajit Das
CWCharles W. Winterbottom
Charles W. Winterbottom
SSShaheen S. Sikandar
Shaheen S. Sikandar
Breast cancer (BC) is the most common type of cancer among females, and the number of deaths due to BC has increased over the past few decades. BC is primarily categorized based on the receptor status of BC cells as hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+), and triple-negative BC (TNBC). These subtypes differ significantly in their treatment strategies, prognosis, immunogenic nature, and response to immunotherapy. TNBC is the most aggressive with a poor prognosis, but a subset of TNBCs that express programmed cell death ligand 1, have shown promising responses to immune checkpoint inhibitors. Across BC subtypes, distinct immune cell subsets remain active in the tumor immune microenvironment (TIME) that either inhibit or promote the growth of cancer. In isolation, it is challenging for cancer cells to thrive in presence of the body’s immune system, however with the aid of other cells in the TIME, they can work together to evade immune detection by suppressing antigen presentation, modulating immune recognition markers, and recruiting immune-suppressive cells. In this review, we provide an overview of the BC immune evasion mechanisms and discuss aspects of immune evasion in relation to tumor heterogeneity and cellular plasticity. We also highlight successful clinical trials targeting immune-evasion markers and discuss the challenges and potential future directions for solving these problems.

25 March 2025
Verified
Book Chapter
Closed access
SASushree Subhadra Acharya
Sushree Subhadra Acharya
SBSubhasmita Bhal
Subhasmita Bhal
BDBiswajit Das
Biswajit Das
CKChanakya Nath Kundu
Chanakya Nath Kundu